Market Overview

Global Oncology Biosimilars Market 2018-2026: Market Share, Applications, Growth Trends, Key Players, Competitive Strategies and Forecasts - ResearchAndMarkets.com

Share:

The "Global
Oncology Biosimilars Market Size, Market Share, Application Analysis,
Regional Outlook, Growth Trends, Key Players, Competitive Strategies and
Forecasts, 2018 To 2026"
report has been added to ResearchAndMarkets.com's
offering.

The global oncology biosimilars market was valued at US$ 1,651.5 Mn in
2017, expanding at a CAGR of 28.3% from 2018 to 2026.

The number of biosimilar approvals soared in the United States as five
of nine approved biosimilars across different disease conditions
received U.S. FDA approval. Furthermore, U.S. witnessed the approvals of
oncology biosimilars such as Amgen's Mvasi (bevacizumab-awwb), a
biosimilar to Genentech's Avastin for the treatment of lung, colorectal,
kidney, brain and cervical cancers; and Mylan's Ogivri
(trastuzumab-dkst), a biosimilar to Herceptin for treating breast
cancer, gastric cancer, and gastrointestinal cancer.

In terms of drug class, the granulocyte colony-stimulating factor
(G-CSF) held the largest share in the oncology biosimilars market owing
to its early approvals in Europe and U.S. However, monoclonal antibodies
class expected to grow at a highest growth rate and emerge as the
largest market in 2026 due to recent approvals of Mvasi
(bevacizumab-awwb) and Ogivri (trastuzumab-dkst) in the United States.
Moreover, robust pipeline and patent expiration of major biologics
during the forecast period would further assist the market growth of
monoclonal antibodies. In terms of disease condition, neutropenia led
the market due to approvals of filgrastim and Peg-filgrastim to multiple
pharmaceutical companies in Europe and Asia Pacific. However, breast
cancer is projected to proliferate at a humungous rate due to high
prevalence of breast cancer globally and recent approval of trastuzumab
in Europe and North America.

Europe dominated the global oncology biosimilars market in 2017 due to
presence of approved oncology biosimilar such as filgrastim, trastuzumab
and rituximab in the region. Moreover, the European Medicines Agency
(EMA) have put forth guidelines for the approval of biosimilars through
regulatory bodies such as European Society of Medical Oncology (ESMO).

North America is anticipated to exhibit rapid growth in oncology
biosimilars market due to market entry of breakthrough oncology
biosimilars and vigorous pipeline expected to hit the market during the
forecast period.

The prominent players actively engaged in the oncology biosimilars
market are Samsung Bioepis, Celltrion Inc., Biocon, Dr. Reddy's
Laboratories Ltd., Intas Pharmaceuticals Ltd., STADA Arzneimittel AG,
Pfizer Inc., Sandoz Inc., Teva Pharmaceutical Industries Ltd., Apotex
Inc., and BIOCAD.

Robust pipeline and ongoing clinical trials in U.S. and Europe are
driving the oncology biosimilars market. For instance, Pfizer has six
biosimilars in phase III of clinical trials, testing for drugs such as
Rituxan/MabThera, Herceptin, Avastin and Humira

Key Market Movements:

  • Rising prevalence of cancer worldwide
  • Recent FDA approved biosimilars contributing towards the growth of
    oncology biosimilars market
  • Patent expirations of major biologics leading to inclination of
    generic pharmaceutical companies to venture in biosimilars
  • Partnerships and collaboration between biopharmaceutical companies to
    increase research and development of biosimilars
  • Robust pipeline of oncology biosimilars anticipated to enter the
    market by 2020 will also assist market growth

Key Topics Covered:

Chapter 1. Preface

Chapter 2. Executive Summary

Chapter 3. Oncology Biosimilars: Market Dynamics and Outlook

Chapter 4. Global Oncology Biosimilars Market, by Drug Class, 2016-2026
(US$ Mn)

Chapter 5. Global Oncology Biosimilars Market, by Disease Condition,
2016-2026 (US$ Mn)

Chapter 6. Global Oncology Biosimilars Market, by Geography, 2016 - 2026
(US$ Mn)

Chapter 7. Company Profiles

  • Amgen, Inc.
  • Mylan N.V.
  • Samsung Bioepis Co. Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Pfizer, Inc.
  • Celltrion Healthcare
  • Novartis International AG
  • Biocon Limited
  • Biogen Idec
  • Sandoz
  • Dr. Reddy's Laboratory
  • Merck & Co.
  • Shanghai Henlius Biotech, Inc.
  • Biocad

For more information about this report visit https://www.researchandmarkets.com/research/pz8xvz/global_oncology?w=4

View Comments and Join the Discussion!